<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05019729</url>
  </required_header>
  <id_info>
    <org_study_id>10000536</org_study_id>
    <secondary_id>000536-I</secondary_id>
    <nct_id>NCT05019729</nct_id>
  </id_info>
  <brief_title>VRC 614: A Phase 1, Dose Escalation, Open-Label Clinical Trial With Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Protective Efficacy of an Anti-Malaria Human Monoclonal Antibody, VRC-MALMAB0114-00-AB (L9LS), in Healt...</brief_title>
  <official_title>VRC 614: A Phase 1, Dose Escalation, Open-Label Clinical Trial With Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Protective Efficacy of an Anti-Malaria Human Monoclonal Antibody, VRC-MALMAB0114-00-AB (L9LS), in Healthy Malaria-Naive Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Malaria is a parasitic disease carried by mosquitoes in tropical areas. There is no vaccine&#xD;
      to prevent malaria infection. If not treated right away, it can become serious or deadly.&#xD;
      Researchers want to test a drug to prevent malaria.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To test if the drug L9LS is safe and if it prevents malaria infection in people.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Healthy adults ages 18-50 who have never had malaria.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will be screened with a medical history, physical exam, and blood tests.&#xD;
&#xD;
      Participants will be divided into 5 groups:&#xD;
&#xD;
        -  Three groups will get L9LS by infusion into a vein. They will give blood samples before&#xD;
           and after infusion.&#xD;
&#xD;
        -  One group will get L9LS injected into the fat under the skin.&#xD;
&#xD;
        -  One group will not get L9LS.&#xD;
&#xD;
      All participants who get L9LS will be monitored for side effects. They will have 2-3&#xD;
      follow-up visits during the week after the drug is given. They will give blood samples. They&#xD;
      will get a thermometer to check their temperature daily for 7 days. They will get a tool to&#xD;
      measure any redness, swelling, or bruising at the injection site.&#xD;
&#xD;
      All participants will be bitten by mosquitoes carrying the malaria parasites. A cup&#xD;
      containing mosquitoes will be placed on their arm for 5 minutes. On days 7-17 after exposure,&#xD;
      they will have daily study visits to give blood samples. Those who get malaria will be&#xD;
      treated immediately. On day 21, all participants will get treatment for malaria.&#xD;
&#xD;
      Participation will last 2-6 months, depending on study group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open-label, dose escalation study to evaluate the safety, tolerability,&#xD;
      pharmacokinetics and protective&#xD;
&#xD;
      efficacy of an anti-malaria human monoclonal antibody, VRC-MALMAB0114-00-AB (L9LS). The&#xD;
      primary hypothesis is that L9LS will be safe and well tolerated when administered by either&#xD;
      intravenous (IV) or subcutaneous (SC) routes. The secondary objectives are that L9LS will be&#xD;
      detectable in human sera with a&#xD;
&#xD;
      definable half-life and confer protection following a controlled human malaria infection&#xD;
      (CHMI).&#xD;
&#xD;
      The study will start with enrollment into Group 1. Interim safety evaluations will occur and&#xD;
      must support continued evaluation of L9LS prior to enrolling subjects into additional dose&#xD;
      groups. All L9LS recipients will participate in the CHMI. Group 5 participants will not&#xD;
      receive investigational product, in order to serve as&#xD;
&#xD;
      the control group for the CHMI. After CHMI, all participants will be evaluated for malaria&#xD;
      parasitemia. Subjects who develop blood stage infection will be&#xD;
&#xD;
      treated as soon as identified per protocol criteria.&#xD;
&#xD;
      Study follow-up will continue through 24 weeks post product administration or 8 weeks post&#xD;
      CHMI, whichever is most stringent.&#xD;
&#xD;
      The groups are:&#xD;
&#xD;
      Group 1: 5 subjects- 1mg/kg IV&#xD;
&#xD;
      Group 2: 4 subjects- 5 mg/kg IV&#xD;
&#xD;
      Group 3: 5 subjects - 5 mg/ kg SC&#xD;
&#xD;
      Group 4: 4 subjects - 20 mg/kg IV&#xD;
&#xD;
      Group 5: 6 subjects - Control&#xD;
&#xD;
      Enrollment of up to 35 subjects is permitted. Two additional subjects will be enrolled as&#xD;
      CHMI back-ups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of L9LS</measure>
    <time_frame>Through 24 weeks after product administration</time_frame>
    <description>5 mg/kg IV of L9LS administered to healthy malaria-naive adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of L9LS</measure>
    <time_frame>Through 24 weeks after product administration</time_frame>
    <description>20 mg/kg IV of L9LS administered to healthy malaria-naive adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of L9LS</measure>
    <time_frame>Through 24 weeks after product administration</time_frame>
    <description>5 mg/kg SC of L9LS will be administered to healthy malaria-naive adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of L9LS</measure>
    <time_frame>Through 24 weeks after product administration</time_frame>
    <description>1 mg/kg IV of L9LS administered to healthy malaria-naive adults.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the phamacokinetics of L9LS at each dose level</measure>
    <time_frame>Throughout the study</time_frame>
    <description>The pharmacokinetics of L9LS administered at each dose level will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine if L9LS confers protection</measure>
    <time_frame>Following CHMI</time_frame>
    <description>To determine if L9LS administered IV or SC confers protection against plasmodium falciparum following CHMI</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/kg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/kg SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/kg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Nothing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg/kg IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VRC-MALMAB0114-00-AB</intervention_name>
    <description>VRC-MALMAB0114-00-AB is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozite protein.</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CHMI</intervention_name>
    <description>Negative control designed to test the infection ability of the CHMI.</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        A subject must meet all of the following criteria to be included:&#xD;
&#xD;
          1. Able and willing to complete the informed consent process&#xD;
&#xD;
          2. Able to provide proof of identity to the satisfaction of the study clinician&#xD;
             completing the enrollment process&#xD;
&#xD;
          3. Available for clinical follow-up through the last study visit&#xD;
&#xD;
          4. 18 to 50 years of age&#xD;
&#xD;
          5. In good general health without clinically significant medical history&#xD;
&#xD;
          6. Physical examination without clinically significant findings within the 56 days prior&#xD;
             to enrollment&#xD;
&#xD;
          7. Weight &lt;= 115 kg (except Group 5)&#xD;
&#xD;
          8. Adequate venous access if assigned to an IV group or adequate subcutaneous tissue if&#xD;
             assigned to an SC group&#xD;
&#xD;
          9. Willing to have blood samples collected, stored indefinitely, and used for research&#xD;
             purposes&#xD;
&#xD;
         10. Agrees to participate in a controlled human malaria infection (CHMI) and to comply&#xD;
             with post-CHMI follow-up requirements&#xD;
&#xD;
         11. Agrees to refrain from blood donation to blood banks for 3 years following&#xD;
             participation in CHMI&#xD;
&#xD;
         12. Agrees not to travel to a malaria endemic region during the entire course of study&#xD;
             participation&#xD;
&#xD;
             Laboratory Criteria within 56 days prior to enrollment:&#xD;
&#xD;
         13. WBC 2,500-12,000/mm3&#xD;
&#xD;
         14. WBC differential either within institutional normal range or accompanied by the&#xD;
             Principal Investigator (PI) or designee approval&#xD;
&#xD;
         15. Platelets = 125,000 500,000/mm3&#xD;
&#xD;
         16. Hemoglobin within institutional normal range or accompanied by the PI or designee&#xD;
             approval&#xD;
&#xD;
         17. Creatinine &lt;= 1.1 x upper limit of normal (ULN)&#xD;
&#xD;
         18. Alanine aminotransferase (ALT) &lt;=1.25 x ULN&#xD;
&#xD;
         19. Negative for HIV infection by an FDA approved method of detection&#xD;
&#xD;
             Laboratory Criteria documented any time during screening, prior to enrollment:&#xD;
&#xD;
         20. Negative sickle cell screening test&#xD;
&#xD;
         21. Electrocardiogram (ECG) without clinically significant abnormalities (examples may&#xD;
             include: pathologic Q waves, significant ST-T wave changes, left ventricular&#xD;
             hypertrophy, any non-sinus rhythm excluding isolated premature atrial contractions,&#xD;
             right or left bundle branch block, advanced A-V heart block). ECG abnormalities&#xD;
             determined by a cardiologist to be clinically insignificant as related to study&#xD;
             participation do not preclude study enrollment&#xD;
&#xD;
         22. No evidence of increased cardiovascular disease risk; defined as &gt;10% five-year risk&#xD;
             by the non-laboratory method&#xD;
&#xD;
             Criteria Specific to Women:&#xD;
&#xD;
         23. Postmenopausal for at least 1 year, post-hysterectomy or bilateral oophorectomy, or if&#xD;
             of childbearing potential:&#xD;
&#xD;
               1. Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test (urine or&#xD;
                  serum) on day of enrollment, and prior to product administration and CHMI, and&#xD;
&#xD;
               2. Agrees to use an effective means of birth control through the duration of study&#xD;
                  participation&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        A subject will be excluded if one or more of the following conditions apply:&#xD;
&#xD;
          1. Woman who is breast-feeding or planning to become pregnant during study participation&#xD;
&#xD;
          2. Previous receipt of a malaria vaccine or anti-malaria monoclonal antibody&#xD;
&#xD;
          3. History of malaria infection&#xD;
&#xD;
          4. Any history of a severe allergic reaction with generalized urticaria, angioedema or&#xD;
             anaphylaxis prior to enrollment that has a reasonable risk of recurrence during the&#xD;
             study&#xD;
&#xD;
          5. Hypertension that is not well controlled&#xD;
&#xD;
          6. Receipt of any investigational study product within 28 days prior to&#xD;
             enrollment/product administration (Note: SARS-CoV-2 vaccines approved by emergency use&#xD;
             authorization are not exclusionary)&#xD;
&#xD;
          7. Receipt of any live attenuated vaccines within 28 days prior to enrollment/product&#xD;
             administration&#xD;
&#xD;
          8. Receipt of any vaccine within 2 weeks prior to enrollment/product administration&#xD;
&#xD;
          9. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or&#xD;
             platelet disorder requiring special precautions) or significant bruising or bleeding&#xD;
             difficulties with intramuscular injections or blood draws&#xD;
&#xD;
         10. History of a splenectomy, sickle cell disease or sickle cell trait&#xD;
&#xD;
         11. History of skeeter syndrome or anaphylactic response to mosquito-bites&#xD;
&#xD;
         12. Known intolerance to chloroquine phosphate, atovaquone or proguanil&#xD;
&#xD;
         13. Use or planned use of any drug with antimalarial activity that would coincide with&#xD;
             study product or CHMI&#xD;
&#xD;
         14. Routine use of antibiotics, or use of antibiotics within 4 weeks prior to CHMI&#xD;
&#xD;
         15. History of psoriasis or porphyria, which may be exacerbated after treatment with&#xD;
             chloroquine&#xD;
&#xD;
         16. Anticipated use of medications known to cause drug reactions with chloroquine or&#xD;
             atovaquone-proguanil (Malarone) such as cimetidine, metoclopramide, antacids, and&#xD;
             kaolin&#xD;
&#xD;
         17. History of Sjogren s syndrome&#xD;
&#xD;
         18. History of chronic or recurrent salivary gland disorder diagnosed by a clinician&#xD;
             (note: an isolated occurrence of parotitis, sialadenitis, sialolithiasis, or of a&#xD;
             salivary gland tumor is not exclusionary)&#xD;
&#xD;
         19. History of therapeutic head or neck radiation&#xD;
&#xD;
         20. Any other chronic or clinically significant medical condition that in the opinion of&#xD;
             the investigator would jeopardize the safety or rights of the volunteer, including but&#xD;
             not limited to: diabetes mellitus type I, chronic hepatitis; OR clinically significant&#xD;
             forms of: drug or alcohol abuse, asthma, autoimmune disease, infectious diseases,&#xD;
             psychiatric disorders, heart disease, or cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard L Wu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>VRC Clinic</last_name>
    <phone>(301) 451-8715</phone>
    <email>vaccines@nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VRC Clinic</last_name>
      <phone>301-451-8715</phone>
      <email>vaccines@nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_000536-I.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Gaudinski MR, Coates EE, Novik L, Widge A, Houser KV, Burch E, Holman LA, Gordon IJ, Chen GL, Carter C, Nason M, Sitar S, Yamshchikov G, Berkowitz N, Andrews C, Vazquez S, Laurencot C, Misasi J, Arnold F, Carlton K, Lawlor H, Gall J, Bailer RT, McDermott A, Capparelli E, Koup RA, Mascola JR, Graham BS, Sullivan NJ, Ledgerwood JE; VRC 608 Study team. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019 Mar 2;393(10174):889-898. doi: 10.1016/S0140-6736(19)30036-4. Epub 2019 Jan 24. Erratum in: Lancet. 2020 May 30;395(10238):1694.</citation>
    <PMID>30686586</PMID>
  </reference>
  <reference>
    <citation>Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Plummer SH, Hendel CS, Novik L, Costner PJ, Mendoza FH, Saunders JG, Nason MC, Richardson JH, Murphy J, Davidson SA, Richie TL, Sedegah M, Sutamihardja A, Fahle GA, Lyke KE, Laurens MB, Roederer M, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Hoffman SL; VRC 312 Study Team. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013 Sep 20;341(6152):1359-65. doi: 10.1126/science.1241800. Epub 2013 Aug 8.</citation>
    <PMID>23929949</PMID>
  </reference>
  <reference>
    <citation>Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, Enama ME, Gordon IJ, Chang LJ, Sarwar UN, Zephir KL, Holman LA, James ER, Billingsley PF, Gunasekera A, Chakravarty S, Manoj A, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, K C N, Murshedkar T, DeCederfelt H, Plummer SH, Hendel CS, Novik L, Costner PJ, Saunders JG, Laurens MB, Plowe CV, Flynn B, Whalen WR, Todd JP, Noor J, Rao S, Sierra-Davidson K, Lynn GM, Epstein JE, Kemp MA, Fahle GA, Mikolajczak SA, Fishbaugher M, Sack BK, Kappe SH, Davidson SA, Garver LS, Björkström NK, Nason MC, Graham BS, Roederer M, Sim BK, Hoffman SL, Ledgerwood JE, Seder RA. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016 Jun;22(6):614-23. doi: 10.1038/nm.4110. Epub 2016 May 9. Erratum in: Nat Med. 2016 Jun 7;22(6):692.</citation>
    <PMID>27158907</PMID>
  </reference>
  <verification_date>October 25, 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malaria Parasitemia</keyword>
  <keyword>Malaria Challenge</keyword>
  <keyword>First in Human</keyword>
  <keyword>Mosquito</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

